These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 30628713)
1. Investigational drugs in HIV: Pros and cons of entry and fusion inhibitors (Review). Venanzi Rullo E; Ceccarelli M; Condorelli F; Facciolà A; Visalli G; D'Aleo F; Paolucci I; Cacopardo B; Pinzone MR; Di Rosa M; Nunnari G; Pellicanò GF Mol Med Rep; 2019 Mar; 19(3):1987-1995. PubMed ID: 30628713 [TBL] [Abstract][Full Text] [Related]
2. New drugs. Pozniak A J HIV Ther; 2008 Jun; 13(2):27-33. PubMed ID: 18953271 [No Abstract] [Full Text] [Related]
3. Current status of antiretroviral therapy. Temesgen Z; Warnke D; Kasten MJ Expert Opin Pharmacother; 2006 Aug; 7(12):1541-54. PubMed ID: 16872258 [TBL] [Abstract][Full Text] [Related]
4. New targets and new drugs in the treatment of HIV. López-Aldeguer J; Aguirrebengoa K; Arribas JR; Esté JA; Kindelán JM Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():25-40. PubMed ID: 16373002 [TBL] [Abstract][Full Text] [Related]
5. Investigational Antiretroviral Drugs: What is Coming Down the Pipeline. Gulick RM Top Antivir Med; 2018 Apr; 25(4):127-132. PubMed ID: 29689540 [TBL] [Abstract][Full Text] [Related]
6. Entry inhibitors and their use in the treatment of HIV-1 infection. Haqqani AA; Tilton JC Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872 [TBL] [Abstract][Full Text] [Related]
7. Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults. Fortin C; Joly V; Yeni P Expert Opin Emerg Drugs; 2006 May; 11(2):217-30. PubMed ID: 16634698 [TBL] [Abstract][Full Text] [Related]
8. Novel HIV-1 fusion inhibition peptides: designing the next generation of drugs. Miyamoto F; Kodama EN Antivir Chem Chemother; 2012 Jan; 22(4):151-8. PubMed ID: 22182762 [TBL] [Abstract][Full Text] [Related]
9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
10. Investigational reverse transcriptase inhibitors for the treatment of HIV. Cory TJ; Midde NM; Rao P; Kumar S Expert Opin Investig Drugs; 2015; 24(9):1219-28. PubMed ID: 26088266 [TBL] [Abstract][Full Text] [Related]
11. Anti-HIV therapy: Current and future directions. Agrawal L; Lu X; Jin Q; Alkhatib G Curr Pharm Des; 2006; 12(16):2031-55. PubMed ID: 16787246 [TBL] [Abstract][Full Text] [Related]
12. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. Hughes A; Barber T; Nelson M J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070 [TBL] [Abstract][Full Text] [Related]
13. HIV Pathogenesis and Treatment - Third International AIDS Society Conference. Susman E IDrugs; 2005 Oct; 8(10):813-5. PubMed ID: 16254799 [No Abstract] [Full Text] [Related]
14. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation. Sierra-Aragón S; Walter H Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875 [TBL] [Abstract][Full Text] [Related]
15. The development of anti-HIV-1 drugs. Lu XF; Chen ZW Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415 [TBL] [Abstract][Full Text] [Related]
16. Anti-HIV therapies early in the pipeline. Bartnof HS BETA; 1999; 12(4):57. PubMed ID: 11367256 [TBL] [Abstract][Full Text] [Related]
17. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection. Özdener AE; Park TE; Kalabalik J; Gupta R Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067 [TBL] [Abstract][Full Text] [Related]